BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study

BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study

Background: Hereditary haemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterised by telangiectases, which cause nasal and gastrointestinal (GI) bleeding, and visceral arteriovenous malformations. Since 2012 bevacizumab, a monoclonal antibody targeting vascular endothelial growth...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophie Dupuis-Girod, Evelyne Decullier, Sophie Rivière, Christian Lavigne, Vincent Grobost, Vanessa Leguy-Seguin, Hélène Maillard, Thierry Chinet, Anne-Emmanuelle Fargeton, Alexandre Guilhem, Ruben Hermann
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207241300828
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/20406207241300828

Similar Items